Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, May 13, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki
Okamura, “Astellas”) will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology...
TOKYO and SAN DIEGO, May 1, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, “Poseida”) today announced that Xyphos Biosciences, Inc., (a wholly...
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 19th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting...
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at the meeting of the Board of Directors held today, it decided to change the definition of core basis in consolidated financial statements...
TOKYO, April 23, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDITM (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of...
Follow us
